Navigation Links
Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
Date:5/28/2008

nformation, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4235

David.Schull@russopartnersllc.com Andreas.Marathis@russopartnersllc.com


SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
9. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
10. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
11. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... N.J. , March 5, 2015 CANTEL MEDICAL ... for its second quarter ended January 31, 2015 on Thursday, ... call to discuss the results at 11:00 AM ET. ... 407-8033 approximately 5 to 10 minutes before the beginning of ... replay of the call will be available from Thursday, March ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... WALTHAM, Mass., Jan. 4, 2011 Syndax Pharmaceuticals, Inc., ... Horobin, M.D., the company,s president and CEO, will present ... 2011 at 10:00 a.m. PT at the Parc 55 ... include the recently reported results from a randomized phase ...
... Jan. 4, 2011 STAAR Surgical Company (Nasdaq: ... and marketer of minimally invasive ophthalmic products, today ... ICL implants in patients has exceeded 200,000.  Since ... used in refractive eye surgery as an alternative ...
Cached Medicine Technology:STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 2STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 3
(Date:3/6/2015)... March 06, 2015 Dr. Amy Reed, who ... a ban on the use of power morcellators ( http://www.morcellatorlawsuit2015.com ... the cancer that prompted the launch of their public health ... week that the 41-year-old mother of six had recently undergone ... in her spine. Dr. Reed had been in remission for ...
(Date:3/6/2015)... March 06, 2015 Sanjay Gupta, ... deliver a keynote address at ATA 2015, the ... and Trade Show and world’s largest telemedicine, telehealth ... neurosurgeon, delivers medical correspondence for several of CNN’s ... and documentaries including his DuPont Award winning WEED ...
(Date:3/6/2015)... Ticket Down is a reliable source for authentic ... Clara, California. This state-of-the-art stadium opened on July 17, ... events. , The “Kick the Dust Up Tour” featuring country ... the west coast and Levi’s Stadium. The show at the ... August 29 and fans of the award-winning artist will be ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 ... the leader in the natural products coffee drinks category, ... 100 Cleanest Packaged Foods Awards for its Double ... puts packaged foods to the test to find the ... they must “taste absolutely delicious.” , “As a company ...
(Date:3/6/2015)... San Jose, California (PRWEB) March 06, 2015 ... cancer is one of the most common forms of ... women worldwide. Breast cancer can be screened through various ... among others. Mammography however remains the gold standard technique ... factors such as cost, time taken for the procedure, ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 2Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 3Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 4Health News:CNN’s Dr. Sanjay Gupta Among Headliners at American Telemedicine Association 2015 Annual Meeting 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 2Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 3Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3
... removed from product -, WAYNE, N.J., May 19 ... of the liquid Leukine(R),(sargramostim) 500 mcg vial has been ... and is now available for patients and physicians,in the ... disodium),which was in the product,s liquid 500 mcg vial ...
... census, Americans office workers spend an average of 52 ... Many recent studies on job satisfaction have shown that ... under artificial light in windowless offices, report reduced job ... make office environments more conducive to productivity and employee ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
... VIEW, Calif., May 19 Alexza,Pharmaceuticals, Inc. ... Jeffrey S.,Williams has rejoined the company in ... Ltd., a wholly owned subsidiary of Alexza. ... the Alexza,subsidiary in Singapore and establishing potential ...
... LLC, the world,s,first mobile voice-activation solution for e-Health ... J. Zecchini as its Chief,Operating Officer and Chief ... be responsible for all operations and technology functions., ... to our MediVoice team," said,Anthony V. Milone, Board ...
... CLARA, Calif., May 19 FLARE Santa,Clara HIV ... (AACI), The Billy DeFrank Center Lesbian and Gay ... Health Department, Asian,& Pacific Islander Wellness Center present ... Thursday, May 22, 2008 from 11 to 2 ...
Cached Medicine News:Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 2Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 3Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 4Health News:Greener offices make happier employees 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3Health News:MediVoice Announces Appointment of Edward J. Zecchini as Chief Operating Officer & Chief Technology Officer 2
... SDS Recall marketing software enables the efficient ... The module also has many built-in time ... auto capitalization of name fields and numerous ... and accurate data input. The pre-defined options ...
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
Medicine Products: